King's College London

Research portal

Strategies for drug repurposing against coronavirus targets

Research output: Contribution to journalReview articlepeer-review

Poppy Smith, Miraz Rahman, Peiqin Jin

Original languageEnglish
Article number100072.
Pages (from-to)1-14
Number of pages14
JournalCurrent Research in Pharmacology and Drug Discovery
Volume3
Published2022

Documents

  • CRPHAR 2022

    CRPHAR_2022.pdf, 2.12 MB, application/pdf

    Uploaded date:25 May 2022

    Version:Final published version

    Licence:CC BY

King's Authors

Abstract

Repurposing regulatory agency approved drugs and investigational compounds with known safety profiles can significantly fast track the drug development timeline over de novo drug discovery, with lower investment requirements and improved attrition rate. These advantages are vital in any epidemic or pandemic situation, where hospital beds are occupied by patients for whom there is no known treatment. Here we examine drug repurposing in the context of human coronaviruses, SARS-CoV, MERS-CoV, and, in particular, SARS-CoV-2, the virus currently causing a continued widespread pandemic with substantial impacts on public health and economy. The key druggable targets explored were those involved in viral entry, viral replication, and viral-induced ARDS, as well as viral proteases, with a focus on the strategy by which the drugs were repurposed.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454